Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
Sponsor study identifier
interventional
N/A
0 countries
N/A
Study Start
May 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2006
Actual (reported)Study Completion
Not reported
Date not reportedPatient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2005
Date type not reportedThis date has not been verified as actual or estimated.
September 12, 2005
Actual (reported)October 3, 2005
Actual (reported)January 2006
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Global Clinical Director Solvay
Solvay Pharmaceuticals
First Submitted
September 12, 2005
First Posted
October 3, 2005
Study Start
May 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2006
Actual (reported)Open Label Extension Study of Bifeprunox
Contact the study team to confirm eligibility.
Last Updated
September 12, 2013
Record last verified: 2007-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: